Avantor, Inc. · NYSE:AVTR

Avantor — Conference Presentation (October 2022)

13 slides from Avantor's conference presentation, October 2022

  1. Slide 1: How will the supply chain need to adapt to support the growth of decentralized clinical trials?

    How will the supply chain need to adapt to support the growth of decentralized clinical trials? Claudia Berron Senior Vice President, Clinical Services Proprietary & confidential

  2. Slide 2: Continued growth of clinical trial landscape with increasing global reach

    Continued growth of clinical trial landscape with increasing global reach Clinical Trials Market Global & multisite trial with strong regional growth Estimate $B #’000 Active Clinical Trials I 6 16 II 8.0% 54.1 III 9 3 3 3 IV 6 39.8 9 4 EU 3 7 8 Americas APAC & AMEA 2021 2025 High-complexity, large-

  3. Slide 3: As DCT adoption increases, global DCT market set to continue growth

    As DCT adoption increases, global DCT market set to continue growth 2019 Global DCT market - $bn* Study Type TA Region 5.7% 7,412 1,856 3,455 628 4,927 3,664 11.5 7.4 2,307 1,812 $bn 1,650 2019 2027 1,332 446 157 Total Interv’l Observ’l Expanded Oncology CV Others US EU APAC LATAM MEA Market Access

  4. Slide 4: Trials are considered DCT when they include specific products and services combined

    Trials are considered DCT when they include specific products and services combined COMPONENTS USED IN x% DCTs* Mobile technology Wearable Web based In home Mobile Mobile 14% Wearable devices devices tech devices healthcare tech Activity tracker Electronic data Blood Remote patient Email collection

  5. Slide 5: Market for digital DCT solutions has boomed since start of pandemic

    Market for digital DCT solutions has boomed since start of pandemic, remaining dynamic, with rapid growth forecast 500+ vendors entering the supply chain with digital DCT solution in Europe and North America* NA & EUR Digital DCT Solution Market - $bn* 9.13 Investments in market grew by 114% in 2020

  6. Slide 6: Growth of HHCN services market facilitates move away from central site

    Growth of HHCN services market facilitates move away from central site, whilst enabling benefits of increased patient centricity Spirometry Skilled Home healthcare market - $bn* 0.33 8.4% Blood draws ECG/EEG 0.22 $bn In-home Vital signs infusions 2021 2026 Telemedicine guided physical exams Source:

  7. Slide 7: Decentralization impacts every step of the clinical workflow

    Decentralization impacts every step of the clinical workflow Clinical Workflow Supply Chain & Service Mgmt. Sample Mgmt. Supply Chain Study Approval Logistics Site Service Testing Data Insights & Mgmt. & Shipment Storage & Planning & Dist. Mgmt. & Processing Analytics Services IMPACT OF DECENTRALISA

  8. Slide 8: Digitization and decentralization go hand in hand

    Digitization and decentralization go hand in hand DECENTRALIZATION & DIGITIZATION PATIENT PRODUCTS DATA ANALYTICS SUPPLY CENTRICITY CHAIN ‒ Enrollment ‒ Intuitive ‒ Fundamental/ ‒ Reduce risk/ ‒ Integration ‒ Engagement ‒ Medical validation increase speed ‒ Visibility ‒ eConsent ‒ Nonmedical ‒ Quali

  9. Slide 9: Does decentralization x digitization = consumerization?

    Does decentralization x digitization = consumerization? DECENTRALIZATION DIGITIZATION Data – Increased choice – Simplicity Patient centricity – Burden reduction – Intuitive products Products = – Convenient participation X – Automatic compliance – Guided activity Supply chain – Compelling engagement

  10. Slide 10: Is the supply chain challenge of consumerization worth rising to?

    Is the supply chain challenge of consumerization worth rising to? – Improved patient recruitment and retention SOFTWARE – Reduced cost – Increased efficiencies TELEMEDECINE LOGISTICS TELEMEDICINE SOFTWARE LOGISTICS – Better patient representation – Superior success rates Collaboration DRUG – Stronge

  11. Slide 11: Our experiences

    Our experiences Decentralized Site-Based Site-Based Hybrid Virtual Supply Chain Complexities Diabetes, MS, Hepatitis B, COVID Phase III c.300 Patients/Trial 2-5 Yr Duration CRO & Sponsor US/EUR/APAC Sites Early, emergent signs of DCT adoption within our customers Adoption curve of virtual DCT soluti

  12. Slide 12: Our experiences

    Our experiences Decentralized Site-Based Site-Based Hybrid Virtual Supply Chain Complexities Diabetes, MS, Hepatitis B, COVID Phase III c.300 Patients/Trial 2-5 Yr Duration CRO & Sponsor US/EUR/APAC Sites Not everyone set up to take full advantage of decentralized clinical trials Still some way to g

  13. Slide 13: Q&A

    Q&A farooq.hussain@avantorsciences.com Proprietary & confidential 13

Avantor — Conference Presentation (October 2022) on 6ix